Circulating Tumor Dna

Detection of circulating tumor DNA using immunoglobulin-based next generation sequencing within an apheresis stem cell sample predicted relapse after autologous stem cell transplantation among patients with diffuse large B-cell lymphoma.

In this video, David R. Gandara, MD, director of the thoracic oncology program at UC Davis Comprehensive Cancer Center, discussed a lecture given by Charles Swanton, MD, PhD, FRCP, FMedSci, FRS, at this year’s virtual International Lung Cancer Conference

The past decade has ushered in major transformations in the prevention, diagnosis and treatment of melanoma.

Private and public coverage of liquid biopsy genomic testing for cancer increased significantly between 2015 and 2019, according to results of a retrospective study published in JNCCN — Journal of the National Comprehensive Cancer Network.

Heterogeneity of serial circulating tumor DNA appeared associated with progressive disease among patients with metastatic breast cancer, according to study findings presented during the ASCO20 Virtual Scientific Program.

Circulating tumor DNA has shown great promise as a blood-based, prognostic biomarker for patients with colon cancer, with detectable levels after resection considered an indicator of elevated risk for recurrence.

Circulating tumor cells appeared independently associated with relapse among patients with stage III melanoma, according to results of a prospective study published in Clinical Cancer Research.

SAN ANTONIO — Detection of circulating tumor DNA after neoadjuvant chemotherapy appeared to independently predict disease recurrence among women with early-stage triple-negative breast cancer, according to preplanned analyses of results from the randomized phase 2 BRE12-158 trial presented at San Antonio Breast Cancer Symposium.

Exciting developments in molecular oncology within the past few months include impressive clinical results of a novel drug that targets RET fusions, evidence for variability in gene mutation allele-specific therapy responses, a novel MEK1 resistance mechanism, and an emerging complexity about differences between oncogenic driver mutations regarding the biology of cancer in a given tissue of origin.

BARCELONA — Blood-based tumor mutational burden measured using circulating tumor DNA appeared associated with outcomes after first-line treatment with pembrolizumab-based therapy for metastatic non-small cell lung cancer, according to study results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.